353 related articles for article (PubMed ID: 2507634)
1. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
Tao MH; Morrison SL
J Immunol; 1989 Oct; 143(8):2595-601. PubMed ID: 2507634
[TBL] [Abstract][Full Text] [Related]
2. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
3. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
Zuckier LS; Chang CJ; Scharff MD; Morrison SL
Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of IgM rheumatoid factor binding to chimeric IgG.
Artandi SE; Canfield SM; Tao MH; Calame KL; Morrison SL; Bonagura VR
J Immunol; 1991 Jan; 146(2):603-10. PubMed ID: 1702808
[TBL] [Abstract][Full Text] [Related]
5. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.
Lund J; Takahashi N; Pound JD; Goodall M; Jefferis R
J Immunol; 1996 Dec; 157(11):4963-9. PubMed ID: 8943402
[TBL] [Abstract][Full Text] [Related]
6. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.
Wright A; Morrison SL
J Exp Med; 1994 Sep; 180(3):1087-96. PubMed ID: 8064227
[TBL] [Abstract][Full Text] [Related]
7. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.
Smith RI; Coloma MJ; Morrison SL
J Immunol; 1995 Mar; 154(5):2226-36. PubMed ID: 7868896
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation of human IgG subclass and mouse IgG2b heavy chains secreted by mouse J558L transfectoma cell lines as chimeric antibodies.
Lund J; Takahashi N; Hindley S; Tyler R; Goodall M; Jefferis R
Hum Antibodies Hybridomas; 1993 Jan; 4(1):20-5. PubMed ID: 8431554
[TBL] [Abstract][Full Text] [Related]
9. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
10. A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha.
Brüggemann M; Teale C; Clark M; Bindon C; Waldmann H
J Immunol; 1989 May; 142(9):3145-50. PubMed ID: 2496159
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
12. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides undergo normal isotype switching after immunization with polysaccharide-protein conjugate vaccines.
Shapiro DA; Threadgill DS; Copfer MJ; Corey DA; McCool TL; McCormick LL; Magnuson TR; Greenspan NS; Schreiber JR
J Immunol; 1998 Oct; 161(7):3393-9. PubMed ID: 9759856
[TBL] [Abstract][Full Text] [Related]
13. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for C mu 2, C mu 3, and C mu 4 domains in the regulation of the interaction of IgM with complement C1q.
Chen FH; Arya SK; Rinfret A; Isenman DE; Shulman MJ; Painter RH
J Immunol; 1997 Oct; 159(7):3354-63. PubMed ID: 9317134
[TBL] [Abstract][Full Text] [Related]
14. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions.
Taylor L; Bachler M; Duncan I; Keen S; Fallon R; Mair C; McDonald TT; Schwarz H
J Leukoc Biol; 2002 Sep; 72(3):522-9. PubMed ID: 12223520
[TBL] [Abstract][Full Text] [Related]
16. Glycobiology: 'the function of sugar in the IgG molecule'.
Dwek RA; Lellouch AC; Wormald MR
J Anat; 1995 Oct; 187 ( Pt 2)(Pt 2):279-92. PubMed ID: 7591992
[TBL] [Abstract][Full Text] [Related]
17. Mapping rheumatoid factor binding sites using genetically engineered, chimeric IgG antibodies.
Bonagura VR; Artandi SE; Agostino N; Tao MH; Morrison SL
DNA Cell Biol; 1992 Apr; 11(3):245-52. PubMed ID: 1567557
[TBL] [Abstract][Full Text] [Related]
18. C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids.
Sandlie I; Aase A; Westby C; Michaelsen TE
Eur J Immunol; 1989 Sep; 19(9):1599-603. PubMed ID: 2792180
[TBL] [Abstract][Full Text] [Related]
19. Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.
Chen TF; Sazinsky SL; Houde D; DiLillo DJ; Bird J; Li KK; Cheng GT; Qiu H; Engen JR; Ravetch JV; Wittrup KD
J Mol Biol; 2017 Aug; 429(16):2528-2541. PubMed ID: 28694069
[TBL] [Abstract][Full Text] [Related]
20. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation.
Lund J; Tanaka T; Takahashi N; Sarmay G; Arata Y; Jefferis R
Mol Immunol; 1990 Nov; 27(11):1145-53. PubMed ID: 2174119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
